Pharmacokinetics and Bioequivalence of Two Powders of Azithromycin for Suspension: A Nonblinded, Single-Dose, Randomized, Three-Way Crossover Study in Fed and Fasting States Among Healthy Chinese Volunteers [0.03%]
两种阿奇霉素颗粒剂型在-fed和空腹健康受试者中的药代动力学及生物等效性非盲法、随机、三周期交叉试验
Junbo Shao,Xingxing Liu,Jing Lin et al.
Junbo Shao et al.
Background and objectives: Azithromycin, a macrolide antibiotic, is commonly used to treat mild-to-moderate bacterial infections. This research aimed to evaluate the pharmacokinetics (PK) properties and bioequivalence (BE...
Randomized Controlled Trial
Drugs in R&D. 2024 Dec;24(4):517-529. DOI:10.1007/s40268-024-00492-4 2024
Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants [0.03%]
健康中国受试者中艾加替莫德注射液和艾加替莫德PH20皮下注射的药代动力学、药效学及安全性研究
Shan Jing,Yu Zhang,Yang Lin et al.
Shan Jing et al.
Background: Efgartigimod, a human immunoglobulin G (IgG)1-derived Fc fragment targeting the neonatal Fc receptor, has been developed into intravenous (IV) and subcutaneous (SC) formulations for treating generalized myasth...
Clinical Trial
Drugs in R&D. 2024 Dec;24(4):505-515. DOI:10.1007/s40268-024-00490-6 2024
Trametinib Sensitivity is Defined by a Myeloid Differentiation Profile in Acute Myeloid Leukemia [0.03%]
急性髓系白血病中 trametinib 敏感性由髓系分化谱型决定
Mathieu Quesnel-Vallières,David C Schultz,Alena Orlenko et al.
Mathieu Quesnel-Vallières et al.
Background and objective: Acute myelogenous leukemia (AML) is a common blood cancer marked by heterogeneity in disease and diverse genetic abnormalities. Additional therapies are needed as the 5-year survival remains belo...
Clinical Assessment of Breast Cancer Resistance Protein (BCRP)-Mediated Drug-Drug Interactions of Sepiapterin with Curcumin and Rosuvastatin in Healthy Volunteers [0.03%]
人 volunters 中评估香朴素与姜黄素和罗苏伐他汀之间由乳腺癌抗性蛋白(BCRP)介导的药物相互作用的临床研究
Lan Gao,Diksha Kaushik,Kimberly Ingalls et al.
Lan Gao et al.
Background and objective: Sepiapterin, also known as PTC923 and CNSA-001, is a synthetic form of endogenous sepiapterin being developed as a novel oral treatment for phenylketonuria. Sepiapterin is a natural precursor of ...
Clinical Trial
Drugs in R&D. 2024 Sep;24(3):477-487. DOI:10.1007/s40268-024-00488-0 2024
A Case Report of JAK Inhibitors Therapy for Adult-Onset Still's Disease with Persistent Pruritic Lesions [0.03%]
Janus激酶抑制剂治疗成人Still病顽固性瘙痒皮疹1例报告
Li Tang,Hongjian Shi,Weijun Liu et al.
Li Tang et al.
Background and objective: Adult-onset Still's disease (AOSD) is a recognized autoinflammatory disorder of unknown etiology. The standard initial management for AOSD includes conventional corticosteroids and disease-modify...
Case Reports
Drugs in R&D. 2024 Sep;24(3):391-394. DOI:10.1007/s40268-024-00487-1 2024
Changes in Early-Phase Clinical Trials in China During 2013-2022: A Review [0.03%]
中国临床试验注册中心2013至2022年早期临床试验的变化及分析：一次回顾性研究
Jianxiong Zhang,Peng Zhang,Haixue Wang et al.
Jianxiong Zhang et al.
Clinical trials on innovative drugs in China have witnessed a stage of rapid development in recent years. The introduction of a number of government policies has stimulated enthusiasm for research and development in the pharmaceutical indus...
Pharmacokinetics, Mass Balance, and Biotransformation of [14C]tinengotinib, A Novel Multi-target Kinase Inhibitor, in Healthy Subjects [0.03%]
新型多靶点激酶抑制剂替纳格尔替尼在健康志愿者体内的药代动力学、质量平衡和生物转化研究
Shumao Ni,Sheng Ma,Yingying Yu et al.
Shumao Ni et al.
Background and objective: Tinengotinib, a novel multi-target small molecule kinase inhibitor, is currently undergoing phase II clinical trial in the USA and China. The purpose of this open-label study was to investigate t...
Comparative Analytical Evaluation of the Proposed Biosimilar FYB206 and its Reference Medicinal Product Keytruda® [0.03%]
候选生物类似药FYB206与原研药物Keytruda®对比分析评价研究报告摘要
Jakob C Stüber,Kerstin Uhland,Alwin Reiter et al.
Jakob C Stüber et al.
Background and objective: Biological medicinal products improve patients' lives, but access is limited, mainly due to high costs. Patents for many existing biological products are expiring, and generic versions, which are...
Comparative Study
Drugs in R&D. 2024 Sep;24(3):447-464. DOI:10.1007/s40268-024-00485-3 2024
Effect of Chronic Dolutegravir Administration on the Trace Amine Profile in Wistar Rats [0.03%]
多替拉韦慢性给药对Wistar大鼠痕量胺图谱的影响
Natasha Henning,Tracy A Kellermann,Carine Smith
Natasha Henning
Background: Dolutegravir (DTG), an integrase strand inhibitor, is currently used as the first-line treatment for HIV. Despite relatively poor tissue penetration, the risk of adverse effects in metabolic and excretory syst...
Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature [0.03%]
针对非V600突变BRAF的治疗：单一机构回顾性分析和文献综述
Hirra A Chaudhary,Timothy L Cannon,Arthur Winer
Hirra A Chaudhary
Background and objective: While successful treatment paradigms for BRAF V600 mutations have been developed, 10% of BRAF mutations are not at V600 and lack a standard treatment regimen. This study summarizes the current bo...